Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

Table 1

Baseline characteristics of participants with or without conbercept pretreatment.

	IVC ()	IVR ()	IVTA ()	value
Sex				0.759
Male (eyes, %)	9 (11, 55%)	13 (13, 68.4%)	10 (11, 57.9%)
Female (eyes, %)	8 (9, 45%)	6 (6, 31.6%)	5 (8, 42.1%)
Age (yrs)
Mean (SD)	60.74 ± 2.63	55.28 ± 5.16	57.49 ± 4.22	0.246
Type of diabetes (case, %)				0.527
1	3 (15.0)	4 (21.1)	2 (10.5)
2	12 (6.0)	10 (52.6)	14 (73.7)
Uncertain		5 (25.0)	5 (26.3)	3 (15.8)
Ocular profile (case, %)
Study eye (left/right)	13/7 (65.0/35.0)	8/11 (42.1/57.9)	6/13 (31.6/68.4)	0.138
Previous history of laser	4 (20.0)	2 (10.5)	2 (10.5)	0.495
Lens status	3 (15.0)	4 (21.1)	2 (10.5)	0.663
Pathogeny (case, %)
Nonclearing vitreous hemorrhage	9 (45.0)	9 (47.4)	8 (42.1)	0.914
Diffuse fibrovascular proliferation	4 (20.0)	3 (15.8)	5 (26.3)	0.125
Traction retinal detachment	7 (35.0)	7 (36.8)	6 (31.6)	0.573
Extent of vitreoretinal adhesion grade (case, %)				0.416
0	0 (0.0)	0 (0.0)	0 (0.0)
1	2 (10.0)	4 (21.1)	5 (26.3)
2	12 (60.0)	9 (47.4)	10 (52.6)
3	6 (30.0)	6 (31.6)	4 (21.1)
Duration of diabetes (y)
Mean (SD)	24.25 ± 6.33	28.76 ± 5.27	25.98 ± 4.6	0.227
Mean BCVA (ETDRS letters)			0.531
Mean (SD)	27.83 ± 6.78	25.31 ± 4.23	28.46 ± 7.55
Snellen equivalent (range)	20/100–HM	20/100–20/2000	20/80–HM
IOP (mmHg)
Mean (SD)	15.24 ± 4.67	.64 ± 6.21	16.35 ± 2.89	0.395
Cardiovascular condition (case, %)	12 (60.0)	10 (52.6)	13 (68.4)	1.103
Hypertension (case, %)	15 (75.0)	11 (57.9)	14 (73.7)	0.587
Cerebral vascular disease (case, %)	5 (25.0)	7 (36.8)	4 (21.1)	0.862